LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES
LJ Costaa, NWCJV Donkb, L Rosinolc, R Popatd, Be semere, J Martinez-Lopezf, D Trancuccig, T Stephensonh, K Chastaing, N Bahlisi
a University of Alabama at Birmingham, Birmingham, United States
b Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
c Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
d University College London Hospitals, NHS Foundation Trust, London, United Kingdom
e University of Tübingen, Tübingen, Germany
f Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas CIBERONC, Madrid, Spain
g Johnson & Johnson Innovative Medicine, Raritan, United States
h Johnson & Johnson Innovative Medicine, Spring House, United States
i Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
Ver másRead
1070
Timeswas read the article
230
Total PDF
840
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 20 | 2 | 22 |
| 2025 6 | 92 | 22 | 114 |
| 2025 5 | 128 | 19 | 147 |
| 2025 4 | 96 | 16 | 112 |
| 2025 3 | 95 | 18 | 113 |
| 2025 2 | 92 | 29 | 121 |
| 2025 1 | 163 | 34 | 197 |
| 2024 12 | 40 | 18 | 58 |
| 2024 11 | 80 | 44 | 124 |
| 2024 10 | 34 | 28 | 62 |
